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Background: Monitoring and effectively improving oncologic integrated care requires dashboard information based on quality registra-
tions. The dashboard includes evidence-based quality indicators (QIs) that measure quality of care. This study aimed to assess the quality of 
current integrated head and neck cancer care with QIs, the variation between Dutch hospitals, and the influence of patient and hospital 
characteristics. Methods: Previously, 39 QIs were developed with input from medical specialists, allied health professionals, and patients’ 
perspectives. QI scores were calculated with data from 1,667 curatively treated patients in 8 hospitals. QIs with a sample size of >400 pa-
tients were included to calculate reliable QI scores. We used multilevel analysis to explain the variation. Results: Current care varied from 
29% for the QI about a case manager being present to discuss the treatment plan to 100% for the QI about the availability of a treatment 
plan. Variation between hospitals was small for the QI about patients discussed in multidisciplinary team meetings (adherence: 95%, range 
88%–98%), but large for the QI about malnutrition screening (adherence: 50%, range 2%–100%). Higher QI scores were associated with 
lower performance status, advanced tumor stage, and tumor in the oral cavity or oropharynx at the patient level, and with more curatively 
treated patients (volume) at hospital level. Conclusions: Although the quality registration was only recently launched, it already visualizes 
hospital variation in current care. Four determinants were found to be influential: tumor stage, performance status, tumor site, and vol-
ume. More data are needed to assure stable results for use in quality improvement. 
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In 2006, the WHO stated that even when health sys-
tems are well-developed and appropriately resourced, 
quality remains a serious concern.1 Therefore, it is im-
portant to gain insight into the care that is provided in 
order to monitor and effectively improve high-quality 
care.2,3 Quality of care can be monitored and mea-
sured by using a dashboard of valid and reliable qual-
ity indicators (QIs).4,5 A QI is defined as “a measur-
able element of practice performance for which there 
is evidence or consensus that it can be used to assess 
the quality, and hence change in the quality, of care 
provided.”6 Many QIs have already been developed 
for oncologic diseases7,8 and nononcologic diseases.9
Head and neck cancer (HNC) is the sixth most 
common cause of cancer worldwide.10 HNC and its treat-
ment have a significant impact on a patient’s well-being 
because HNCs grow relatively quickly in an anatomi-
cally and functionally complex location.11–14 Patients of-
ten experience problems with speech, swallowing, and 
physical disfiguration due to surgery, systemic therapy, 
radiation, or a combination of these treatments.15–19 For 
an optimal result, it is crucial that medical specialists 
and allied health professionals (AHPs) deliver integrat-
ed care throughout the care process. 
In 2014, a dashboard in the form of a quality reg-
istration, with census- and evidence-based QIs, was 
developed for measuring the quality of integrated 
care for patients with HNC, (eg, the Dutch Head 
and Neck Audit [DHNA]).20 The start-up of a qual-
ity registration takes several years before stable data 
can be obtained.21 In addition to stable data, insight 
into determinants that influence variation in care at 
the patient and hospital levels can provide tools for 
explaining the QI scores and improving current care 
through medical staff learning from each other.22
This is the first article with results from the DH-
NA—a recently launched quality registration that 
collects data prospectively. We aimed to obtain in-
sight into the quality of currently delivered HNC 
care in the Netherlands and some of the influenc-
ing characteristics to test the value of the QI set as 
an instrument for monitoring and improving clinical 
performance for this quality registration.23
Methods
Study Design
This is a prospective, observational, multicenter study 
for measuring current quality of integrated HNC care 
with a recently launched quality registration, including 
39 census- and evidence-based QIs.20 We determined 
hospital variation in QI scores and explored this varia-
tion to explore whether differences at the patient and 
hospital levels would explain these variations. The 
Medical Ethical Committee of the region Arnhem–Ni-
jmegen declared that ethical approval was not necessary.
Setting
In the Netherlands, approximately 3,000 patients are 
diagnosed with HNC annually. HNC care is central-
ized to 14 hospitals: 8 head and neck oncology centers 
(HNOCs) and 6 affiliated centers.24 The number of 
patients treated annually varies between 70 and 600 
per center. Medical specialists and AHPs involved in 
HNC care are united in 2 national foundations: one 
for medical specialists and another for AHPs; there is 
also a Dutch HNC patient association. 
Study Population
All patients with newly diagnosed HNC from De-
cember 2013 to January 2017 who were treated with 
curative intention in 1 of the 14 hospitals were eli-
gible for registration in the DHNA. 
QI Set
All 39 QIs of the DHNA had been systematically 
developed and based on national and international 
evidence-based guidelines. The Rand modified Del-
phi method was used for this purpose by the 2 na-
tional foundations for medical specialists and AHPs, 
and by the patient association.20 This resulted in 5 
outcome indicators (survival, recurrence, complica-
tion rate, and patient-reported outcomes and expe-
riences), 13 process indicators from the perspective 
of medical specialists (performance in the diagnos-
tic, treatment, and follow-up phases, as well as as-
pects regarding coordination and communication), 
18 process indicators from the perspective of AHPs 
(malnutrition screening and involvement of speech 
therapist), and 3 structure indicators from the per-
spective of AHPs (number of available case man-
agers and nurses for each hospital). In addition, 10 
determinants at patient level and 1 at hospital level 
were selected (see following section). 
Data Collection
The 14 hospitals were encouraged to have all pa-
tients treated for HNC self-register online in the 
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DHNA. Health professionals working in the par-
ticipating hospitals used this registration system to 
collect the necessary data for calculating QI scores 
and assessing determinants at the patient and hos-
pital levels. Determinants were subdivided into the 
following categories: age (continuous), sex, smok-
ing (never, former, or current smoker), alcohol con-
sumption (never, former, or current drinker), WHO 
performance status (PS; 0 vs 1–4), tumor site (oral 
cavity and oropharynx; larynx and hypopharynx; or 
other); clinical TNM stage (early [stage I–II] vs ad-
vanced [stage III–IV]); and comorbidity (yes vs no) 
at patient level, and the volume of HNOCs and af-
filiated centers (<200 patients vs ≥200 patients) at 
hospital level. Volume was defined as the average cu-
ratively treated patients per year in the HNOCs and 
affiliated centers25,26 as registered by the Netherlands 
Comprehensive Cancer Organisation (IKNL).27
Sample Size
Previous research shows that the precision of a QI 
score depends on the number of patients included 
(numerator).28 Therefore, only QIs with a numera-
tor of >400 patients were included for calculating a 
precise indicator score with a confidence limit of ±5 
percentage points.
Data Analyses 
Inclusion criteria for the analysis were: (1) patients 
who underwent curative treatment, (2) availability 
of sufficient data (at least patient age and date of first 
treatment initiation), and (3) at least 30 patients per 
hospital (Figure 1).29 The last criterion assured that 
results were not skewed unfairly because of too few 
data points. 
Descriptive Analyses: The following were assessed 
for each indicator: 
• Denominator: total number of patients who 
should have received the care as recommended 
in the QI
• Indicator score: quotient of the number of pa-
tients who received care as recommended in the 
QI compared with the number of patients who 
needed to receive the care as recommended
• Missing data: percentage of missing values per 
indicator. Missing data for indicators may bias 
the results. A percentage >25% refers to poor 
data quality30 
Determinant Analyses: To assess determinants at 
the patient and hospital levels, we first studied the 
single relationship between indicators (eg, percent-
age of patients discussed in the multidisciplinary 
team meeting [MDT] before start of treatment) and 
determinants that could influence the indicator score 
(eg, tumor site) using a generalized linear mixed 
model. This model accounts for the nested structure 
of data, because individual patients (patient level = 
1) are nested within hospitals (hospital level = 2). 
Determinants that had a univariate relationship of 
P<.20 were assumed to have a potential association 
with the indicator score and were selected as possible 
determinants for the multivariate model.
We tested all of the selected determinants to-
gether in a multilevel logistic regression model or 
multivariate model. Patients were automatically ex-
cluded (list-wise deletion) from the analysis if indi-
cator or determinant data were missing. Missing was 
defined as the state in which data were randomly 
missing, and was tested by comparing the population 
included for the analysis with the original popula-
tion of the study. We needed a minimum of 10 pa-
tients for each degree of freedom in the model to de-
velop a reliable multilevel model. Odds ratios with 
95% CIs described the association between indicator 
scores and determinants. 
Indicator scores were recalculated for each in-
dicator and for each part of the associated determi-
nant. For example, an indicator could be recalculat-
ed for all patients with an early tumor stage and for 
all patients with an advanced tumor stage. If mul-
tiple determinants were associated with a single indi-
cator, for example tumor stage and PS, we combined 
Patients were treated curatively
N=2,351
Sufcient dataa were registered for each patient
N=1,685
Registration of at least 30 patients for each hospital
N=1,667
Figure 1. Inclusion of patients in this study. 
aAt least the age and date of the start of the first treatment are 
known.
© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 16   Number 12 | December 2018
Original Research
van Overveld et al
1494
the different determinants and calculated stratified 
scores for the different categories.
Results
Study Population 
In total, 1,667 patients satisfied the inclusion criteria 
for this analysis. Patients originated from 5 HNOCs 
and 3 affiliated centers. Median patient age was 
65 years (range, 64–68 years) and most were male 
(68.5%; range, 60%–72%) (Table 1). Missing data 
for most patient characteristics varied between 0% 
and 32%; however, 75% of the comorbidity data 
were missing. Regarding volume, 3 of 8 HNOCs and 
affiliated centers were classified as low-volume cen-
ters (<200 curatively treated patients) (results not 
shown). However, not all hospitals were able to reg-
ister all treated patients (Table 2).
Current HNC Care and Variation
A total of 9 process indicators had a numerator of >400 
patients: 7 from the medical specialist perspective and 
2 from the AHP perspective (Table 3). The indicator 
for a case manager or nurse practitioner being present 
at the consultation to discuss the treatment plan had 
the lowest score and a high variation (adherence to QI-
9: 28.9%; range, 0%–90%), and the indicator for the 
availability of a treatment plan had the highest score 
(adherence to QI-2: 100%; no range). The scores of 3 
process indicators for an MDT and a treatment plan 
had an adherence of >90%, and the variation between 
hospitals was small, particularly for an MDT before 
treatment (QI-1: 95.4%; range, 88%–98%), availabil-
ity of a treatment plan (QI-2: 100%; no range), and 
registration of whether the patient was treated accord-
ing to protocols (QI-3: 97.2%; range, 86%–99%). The 
scores of 3 lead-time indicators varied between 48.4% 
and 82.6% adherence, with the lowest score for start-
ing the first treatment within 30 calendar days from 
first consultation (QI-7: 48.4%; range, 24%–78%) and 
the highest score for finishing diagnostics within 21 
calendar days (QI-6: 82.6%; range, 63%–100%). Vari-
ation between hospitals was greatest for malnutrition 
screening (QI-8: 49.9%; range, 2%–100%). Three 
indicators had >25% of missing data: involvement of 
a dental team before radiotherapy, start of first treat-
ment within 30 days of first consult, and malnutrition 
screening before treatment. 
Determinants
Comorbidity, nationality, and marital status had 
≥75% missing data and were therefore excluded from 
Table 1. Patient Characteristics
Results Missing  
Dataan % (Range)
Median age at start  
of treatment
1,667 65 y (64–68 y) 0%
Sex  0.1%
Male 1,142 68.5% (60%–72%)
 Female 524 31.5% (29%–40%)
Tobacco smoking  28.7%
Never-smoker 220 18.9% (15%–34%)
Former smoker 462 39.7% (18%–43%)
Current smoker 483 41.5% (33%–65%)
Alcohol consumption 27.5%
Never drinker 272 23.4% (11%–41%)
Former drinker 88 7.6% (5%–18%)
Current drinker 801 69.0% (41%–76%)
WHO performance status 32.0%
None 80 8.5% (1%–97%)
1–4 862 91.5% (3%–100%)
Score 0.8%
0 (perfect health) 570 66.7% (10%–92%)
 >0 285 33.3% (8%–90%)
Tumor site 0.1%






Other 293 21.0% (16%–32%)
Clinical TNM stage 21.1%
Early (stage ≤II) 582 47.1% (39%–59%)
Advanced (stage >II) 654 52.9% (39%–66%)
Comorbidity 75.0%
Yes 415          0%b
No 0
aLow percentages registered in the category “unknown” are not 
presented.
bDue to problems with the registration system, we were unable to 
perform any further calculations.











aDuring this period, data were registered in the audit for each 
hospital.
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further analysis. Multilevel analyses showed that 3 
determinants at patient level (tumor stage, tumor site, 
and PS) and 1 determinant at hospital level (hospital 
volume) influenced the scores of 6 indicators signifi-
cantly (Table 3). Patients with advanced tumor stage 
or with tumors in the oral cavity and oropharynx 
compared with the larynx and hypopharynx showed 
greater adherence to indicator scores for involvement 
of the dental team (QI-4; exclusion of T1 larynx car-
cinoma), completing diagnostics within 21 calendar 
days (QI-6), malnutrition screening (QI-8), and a 
case manager or nurse practitioner being present at 
the consultation to discuss the treatment plan (QI-9). 
Imperfect health (high PS) was associated with low 
indicator scores for malnutrition screening. High-vol-
ume centers were associated with better adherence to 
indicator scores for registration of whether the patient 
had been treated according to the protocol (QI-3), for 
referral to the hospital within 7 calendar days (QI-5), 
and for completing diagnostics within 21 calendar 
days (QI-6). Stratified QI scores varied from the origi-
nal QI scores (Tables 3 and 4). The lowest increase of 
adherence, from 28.9% to 30.4%, was seen for QI-9 
(presence of a case manager or nurse practitioner at 
the consultation). The greatest increase of adherence, 
from 49.9% to 81.9%, was seen for the QI-8 (malnu-
trition screening).
Discussion
This study aimed to assess the variation of current HNC 
care between Dutch hospitals and the influence of pa-
tient and hospital characteristics. Quality of current 
care was low for the QI regarding the presence of a case 
manager at the consultation to discuss the treatment: 
the case manager was present in nearly one-third of all 
hospitals. Hardly any variation was seen between hospi-
tals regarding the QI for the percentage of patients dis-
cussed in the MDT. However, almost all hospitals scored 
differently, varying from 2% to 100%, for the malnu-
trition screening QI. Four characteristics at patient and 
hospital levels had a large influence on indicator scores: 
tumor stage, PS, tumor site, and hospital volume. 
Previous research shows that care, despite nation-
al guidelines, is not always delivered the same way in 
different hospitals.31,32 We also found large variation in 
care delivery from the perspectives of medical special-
ists and AHPs. The largest variation was for QIs from 
the perspective of AHPs, perhaps because of the lack 
of evidence-based guidelines. Regarding patient charac-
Table 3. Results of Indicators From Medical Specialist and AHP Perspectives










Influencing Patient and 
Hospital Characteristics
1 MDT meeting occurs before  
treatment (MS)
877 95.4 88–98 14.1a None
2 Treatment plan available (if patient 
discussed in MDT meeting before start 
of treatment) (MS)
836 100 0 18.1b NA
3 Registration of whether patient was 
treated according to protocols (MS)
835 97.2 86–99 17.7 Hospital volume
4 Involvement of dental team before 
start of radiotherapy (MS)c
713 83.7 67–100 25.1d Tumor stage 
5 Referral to hospital (within 7 calendar 
days) (MS)
975 79.6 53–100 4.5 Hospital volume 
6 Finishing diagnostics (within 21 
calendar days) (MS)
1,010 82.6 63–100 1.1 Tumor site and hospital 
volume 
7 Start of first treatment (within 30 
calendar days) from first consult (MS)
978 48.4 24–78 26.3 None
8 Malnutrition screening at intake or 
before start of treatment (AHP)
619 49.9 2–100 39.4a Tumor stage and 
performance status 
9 Presence of case manager/nurse 
practitioner at consultation to discuss 
treatment plan (AHP)
1,013 28.9 0–90 0.8a Tumor site
Abbreviations: AHP, allied health professional; MDT, multidisciplinary team; MS, medical specialist; NA, not applicable; QI, quality indicator.
aPatients for whom at least the intention of the treatment was clear and for whom diagnostics were carried out.
bPatients for whom at least the intention of the treatment was clear, diagnostics were carried out, and there was a treatment plan.
cExclusion of patients diagnosed with T1 glottic carcinoma. 
dPatients for whom at least the intention of the treatment was clear, and they were treated with radiotherapy.
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teristics, a small increase was seen in the stratified QI 
scores for the single determinants of tumor stage and 
site compared with the raw QI scores. However, if the 
QIs were calculated for both different tumor stage and 
PS, the stratified QI score was much greater than the 
raw QI score. Both determinants are often used for case 
mix correction.33 If indicators are to be used to compare 
quality of care between hospitals, adjustment of the in-
dicator scores might be needed. When more data are 
available, the prognostic value of patient characteris-
tics for survival could be investigated. Regarding hospi-
tal characteristics, previous studies show an association 
between varying hospital volume and survival.25,34 We 
determined the influence of hospital volumes on our QI 
set and found it had a positive influence on lead time 
and registration if a patient was treated according to the 
protocols. In the future, the association between volume 
and patient outcomes, such as survival and recurrence 
percentage, can also be assessed for patients with HNC 
to investigate whether further concentration of HNC 
care in the Netherlands is beneficial. In addition, more 
research must be conducted regarding the characteris-
tics of low-volume and high-volume hospitals and the 
association with indicators in order to obtain points of 
interest to improve care.
Table 4.  Influenced Scores of Indicators in the Multilevel Analyses and Corresponding Stratified Indicator Score
QI Topic – Indicators
Patient  and Hospital 
Characteristic n OR (95% CI)a Indicator Score (%)a
3 Registered whether patient 
was treated according to 
protocol
Hospital volume 138 Low volume: Ref Low volume: 93.2
674 High volume: 2.255 (1.073–4.740) High volume: 99.0
4 Involvement of dental 
team before start of 
radiotherapya
Tumor stage 204 Early-stage: Ref Early-stage: 72.5
411 Advanced-stage: 3.066 (1.901–4.946) Advanced-stage: 90.3
5 Referral to hospital (within 
7 calendar days)
Hospital volume 1,096 Low volume: Ref Low volume: 57.1
67 High volume: 3.521 (1.722–7.196) High volume: 85.1
6 Completing diagnostics 
(MDT; within 21 calendar 
days)
Tumor site 220 Other: Ref Other & low volume: 55.8
485 O/O: 1.710 (1.102–2.652) O/O & low volume: 70.3
304 L/H: 0.889 (0.564–1.399) L/H & low volume: 62.3
Hospital volume 135 Low volume: Ref Other & high volume: 86.4 
699 High volume: 3.692 (1.342–10.162) O/O & high volume: 90.6
L/H & high volume: 82.1
8 Malnutrition screening at 
intake or before start of 
treatment
Tumor stage 220 Early: Ref Early-stage & PS 0: 56.6
309 Advanced: 4.110 (2.466–6.849) Early-stage & PS >0: 23.6
PS 270 PS 0: Ref Advanced-stage & PS 0: 81.9
199 PS >0: 0.595 (0.356–0.995) Advanced-stage & PS >0: 38.1
9 Presence of case manager 
or nurse practitioner at 
consultation to discuss the 
treatment plan
Tumor sitea 204 Other: Ref Other: 37.7 
426 O/O: 0.627 (0.403–0.974) O/O: 30.8
280 L/H: 0.487 (0.303–0.781) L/H: 30.4
Abbreviations: L/H, larynx and hypopharynx; MDT, multidisciplinary team; O/O, oral cavity and oropharynx; OR, odds ratio; PS, performance status; 
QI, quality indicator.
aExclusion of patients diagnosed with T1 glottic carcinoma.
Other countries already have databases with the 
aim of improving quality of care and patient out-
comes, such as the National Head and Neck Cancer 
Audit in the United Kingdom and the Danish Head 
and Neck Cancer database.35,36 A difference with our 
database is that the DHNA relies on census- and ev-
idence-based QIs from the 3 different perspectives 
of medical specialists, AHPs, and patients, whereas 
the other databases are mostly set up from an epi-
demiologic perspective and form a base for clinical 
trials. An epidemiologic database is not primarily 
intended for quality registration. In addition to our 
initiative with quality-of-care data, de Ridder et al31 
published a retrospective cohort evaluation study 
about the variation in HNC care in the Netherlands, 
showing hospital variation in volume and treatment 
of oropharyngeal and oral cavity cancer. However, 
conclusions were drawn from retrospective data that 
were collected for a purpose other than quality regis-
tration. The set up and prospective character of the 
DHNA makes it far more suitable for measuring and 
monitoring the quality of HNC care.
Low indicator scores do not necessarily mean 
that the quality of care is poor; rather, it is a signal 
to evaluate further. Dentler et al37 define good-qual-
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ity data as being available, complete, and correct. 
Further, they show that data quality can influence 
indicator results. Our quality registration is in the 
start-up phase. The quality of our data does not 
seem optimal. Regarding completeness, it is crucial 
to include all patients with HNC to conclude any-
thing about general healthcare.38 At the moment, 
registration is not complete, although all 14 hos-
pitals were encouraged to register all patients with 
HNC treated in their hospital. Centers with low 
inclusion must be encouraged to include all pa-
tients. Completeness will be increased when feed-
back on indicator scores is actually used in hospitals 
and when these scores begin improving. Regarding 
availability, we excluded 666 patients (2,351 minus 
1,685) due to insufficient data in the first step (Fig-
ure 1). This can be explained by the start-up phase 
of the registration in which hospitals are still figur-
ing out how to collect data efficiently, resulting in 
incomplete records and incomplete patient inclu-
sion. We assume that these patients’ data are miss-
ing at random. Hereafter, the indicator with the 
highest number of included patients had a denomi-
nator of 1,013 patients. We assume that the differ-
ence between 1,685 and 1,013 patients is also ran-
dom, due to a high registration burden and health 
professionals stopping halfway in the registration 
system. However, the percentage of missing data for 
the indicator scores, varying from 1.1% to 39.4%, 
might be due to high registration burden or to the 
fact that data were missing in the electronic record, 
such as the percentage of patients who received a 
malnutrition screening at predefined moments. It 
might be possible that health professionals skipped 
the section on malnutrition screening in the reg-
istration system. This type of missing data may 
also be random, because it would not depend on 
the type of patients. Regarding the missing data for 
the determinants, we take into consideration that 
most of the missing data will also be random due 
to the start-up phase and high registration burden. 
Regarding correctness, data from the DHNA will 
be compared with data from the Netherlands Can-
cer Registry, which is managed by the Netherlands 
Comprehensive Cancer Organisation. However, in 
the past years, the online self-registration system 
has improved due to the optimizing of registration 
guidelines, the learning curve of health profession-
als, and the exploring of links between electronic 
patient record systems and the DHNA database. 
Therefore, better data quality is expected in the fu-
ture. Hereafter, all indicators could be evaluated, 
rather than only the best-performing indicators.
Strengths and Limitations
A strength of this study is that it enabled census- and 
evidence-based QI scores to be assessed for nearly 
1,700 patients. Because only indicators with a numer-
ator of >400 were taken into account for calculating 
a precise indicator score, insight into the total quality 
of care for patients with HNC was impossible. In ad-
dition, data quality criteria, such as availability, com-
pleteness, and correctness, need further improvement. 
We will achieve this by giving feedback about missing 
data and indicator scores, advising on improvement 
processes, and validating the registered data. Further-
more, more data are necessary to perform a reliable 
case mix correction. However, we assume that the case 
mix will be comparable between the different partici-
pating hospitals for the following reasons: (1) distribu-
tion across the 14 hospitals is largely geographic and 
not based on specific expertise, and (2) Dutch health 
insurance is based on a social system with basic assur-
ance for each citizen, and therefore it is unlikely that 
there is an association between socioeconomic status 
and quality of care. Lastly, based on the opinions of 
the caregivers involved in the registration, collection 
of data seems to be difficult and time-consuming. Fo-
cus on less labor-intensive registration systems and 
more automatic data collection is needed, particularly 
registration at the source. Initiatives in the United 
States and the Netherlands have already started.39,40
Conclusions
Initiating a multidisciplinary quality registration 
system based on census- and evidence-based QIs is 
challenging; the main requirements are guidelines 
for developing QIs and sufficient data to evaluate 
the QIs, determine case mix, and assess the effects 
of variation on outcomes. However, our recently 
launched audit already visualizes the variation in 
current care among hospitals that deliver HNC 
care. One of the next steps for the DHNA will be 
to conduct more research to explore the association 
between variation in quality of care and differences 
in patient outcomes and to identify targets for qual-
ity improvement.
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